Loading
Everything OnCo dates to 1999: 74 entries, 25 landmarks, 16 approvals, 10 papers listed on people's pages and 8 companies founded. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
74 dated entries in OnCo fall in 1999: 25 landmarks, 16 approvals, 10 papers listed on people's pages, 8 companies founded, 5 journals founded, 5 papers, 3 technologies and 2 trials reported.
Of those, 74 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Cutaneous lesions of AIDS-related Kaposi sarcoma (topical gel)
Reduction of moderate to severe xerostomia from post-operative radiotherapy for head and neck cancer
Actinic keratoses of the face and scalp with blue-light photodynamic therapy (Levulan Kerastick)
Cutaneous manifestations of cutaneous T-cell lymphoma refractory to at least one systemic therapy
Conditioning with cyclophosphamide before allogeneic HPC transplantation for CML (Busulfex)
Reduction of adenomatous colorectal polyps in familial adenomatous polyposis (accelerated approval; indication withdrawn 2011)
Persistent or recurrent CD25-positive CTCL (Ontak; withdrawn 2014)
Adjuvant therapy for axillary node-positive breast cancer
Advanced breast cancer after tamoxifen
Palliative treatment of skin manifestations of cutaneous T-cell lymphoma unresponsive to other therapy, by extracorporeal photopheresis
Ovarian cancer refractory to platinum and paclitaxel
Prophylaxis of organ rejection in kidney transplant recipients
Irresectable soft-tissue sarcoma of the limbs with melphalan via isolated limb perfusion, as an adjunct to surgery or for palliation
Gastric cancer; later colorectal, head and neck, lung, pancreatic, biliary and breast cancer (TS-1)
Temodal; malignant glioma (recurrent 1999; newly diagnosed glioblastoma with radiotherapy 2005); 26 Jan 1999
Refractory anaplastic astrocytoma
The year reported on trial records, with the headline result the record gives.
Median survival 23 against 19 months (p=0.04); five-year survival 26 against 16 percent; grade 3 oesophagitis 27 against 11 percent.
Relative risk of death 0.84 (95 percent confidence interval 0.73 to 0.97, p=0.01); three-year survival 20.7 against 15.3 percent.
The publication year on key paper records.
Rose PG, Bundy BN, Watkins EB, et al. New England Journal of Medicine.
Aupérin A, Arriagada R, Pignon JP, et al. New England Journal of Medicine.
Sherr CJ, Roberts JM. Genes and Development.
Turrisi AT, Kim K, Blum R, et al. New England Journal of Medicine.
Hutchins LF, Unger JM, Crowley JJ, et al. New England Journal of Medicine.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Inflammatory myofibroblastic tumour (IMT). Griffin and colleagues identify 2p23 rearrangements, the first ALK fusions outside lymphoma.
Early hepatocellular carcinoma (BCLC 0 and A)
Hepatocellular carcinoma
Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)
High-risk neuroblastoma
Neuroblastoma (paediatric)
Vaginal cancer. Five randomised trials; the approach is extrapolated to vaginal cancer.
Vaginal squamous cell carcinoma (HPV-associated)
Chronic lymphocytic leukaemia. Hamblin and Damle show unmutated IGHV means aggressive disease.
Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)
Early gastric cancer
Locally advanced cervical cancer
Cervical cancer. Five randomised trials show 30-50% mortality reduction; chemoradiation becomes standard for locally advanced disease.
Ductal carcinoma in situ (DCIS)
Nasopharyngeal carcinoma
Small-cell lung cancer
Early cervical cancer and fertility-sparing surgery
Lung cancer (all types). Twice-daily thoracic radiotherapy raised five-year survival from 16 to 26 percent in limited-stage disease, and the prophylactic cranial irradiation overvi...
Glioma & glioblastoma
Multiple myeloma
Limited-stage small-cell lung cancer
Small-cell lung cancer
Thymic carcinoma
Thymoma and thymic carcinoma
Thymoma (WHO types A, AB, B1, B2 and B3)
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Brussels
Paris
Cambridge, MA
Tours
Paris
Ames, Iowa, United States
New York, NY
San Francisco, CA
The founded year on journal records.
BMC (Springer Nature)
Elsevier
Springer
Elsevier
Oxford University Press
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Nature Medicine
Annals of Surgery
Science
Journal of Pathology
JCO
Science
Journal of Virology
Stroke
JNCI: Journal of the National Cancer Institute
New England Journal of Medicine